SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (840)5/12/1997 6:31:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Rick, the stage could be setting with the relativly poor biotech/ FDA showings for a company such as Idec to turn the tide with the FDA and the investment community. The few drugs that have been recently approved have dissappointed investors with weak mkt penetration as far as early revenue numbers. Agouron Pharm should be the exception in this area but they do have tough competition from the likes of Merck. What I believe investors are missing in their analysis of Idec is that C2B8's competition is chemo/radiation in which nhl patients are strongly looking for alternative therapies that are just as efficacious but less toxic. My belief is that Idec could be the spark that highlights the biotechs as far as FDA approval, but also as great potential for early and significant penetration into the NHL marketplace. I know you get some good insight and keep us posted on anything that comes your way.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News